Why the study?
Studies on serum leucine-rich alpha-2 glycoprotein (LRG) in IBD are scarce, and methods for estimating disease activity are less established, particularly for CD.
Is serum leucine-rich alpha-2 glycoprotein (LRG) a useful inflammatory biomarker for assessing disease activity in inflammatory bowel disease?
Is serum leucine-rich alpha-2 glycoprotein (LRG) a useful inflammatory biomarker for assessing disease activity in inflammatory bowel disease?
Serum LRG is a promising inflammatory biomarker that correlates with clinical and endoscopic disease activity in patients with ulcerative colitis and Crohn's disease.
No takes yet. Share an insight, caveat, or question.
LRG may support noninvasive IBD activity monitoring; leaves open prospective validation against CRP before clinical adoption.
Yoshimura et al. (2021) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: